IL300854A - Treatment of non-small cell lung cancer with EGFR mutations - Google Patents
Treatment of non-small cell lung cancer with EGFR mutationsInfo
- Publication number
- IL300854A IL300854A IL300854A IL30085423A IL300854A IL 300854 A IL300854 A IL 300854A IL 300854 A IL300854 A IL 300854A IL 30085423 A IL30085423 A IL 30085423A IL 300854 A IL300854 A IL 300854A
- Authority
- IL
- Israel
- Prior art keywords
- egfr
- cancer
- seq
- mutation
- met
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069748P | 2020-08-25 | 2020-08-25 | |
| PCT/IB2021/057794 WO2022043895A2 (en) | 2020-08-25 | 2021-08-25 | Treatment of non-small lung cancer with egfr mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300854A true IL300854A (en) | 2023-04-01 |
Family
ID=80352814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300854A IL300854A (en) | 2020-08-25 | 2021-08-25 | Treatment of non-small cell lung cancer with EGFR mutations |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12528869B2 (https=) |
| EP (1) | EP4204455A4 (https=) |
| JP (1) | JP2023539589A (https=) |
| KR (1) | KR20230053686A (https=) |
| CN (1) | CN116194141A (https=) |
| AU (1) | AU2021330539A1 (https=) |
| CA (1) | CA3192922A1 (https=) |
| IL (1) | IL300854A (https=) |
| JO (1) | JOP20230039A1 (https=) |
| MX (1) | MX2023002362A (https=) |
| WO (1) | WO2022043895A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230174677A1 (en) * | 2021-11-16 | 2023-06-08 | Janssen Biotech, Inc. | Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL) |
| WO2024003837A1 (en) * | 2022-06-30 | 2024-01-04 | Janssen Biotech, Inc. | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer |
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| CN116284335A (zh) * | 2023-03-17 | 2023-06-23 | 云南中医药大学 | Egfr基因突变体的检测方法及应用 |
| WO2025158277A1 (en) * | 2024-01-22 | 2025-07-31 | Janssen Biotech, Inc. | Use of amivantamab to treat head and neck cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT3904391T (pt) | 2010-03-10 | 2024-10-14 | Genmab As | Anticorpos monoclonais contra c-met |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| WO2012142535A2 (en) | 2011-04-15 | 2012-10-18 | Esco Corporation | Replaceable wear parts for an earth-working roll |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| US20170275367A1 (en) * | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| KR102771603B1 (ko) | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| WO2020102647A1 (en) | 2018-11-15 | 2020-05-22 | Invenra Inc. | Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| BR112023018278A2 (pt) | 2021-03-09 | 2023-10-31 | Janssen Biotech Inc | Tratamento de cânceres sem mutações de ativação de egfr |
-
2021
- 2021-08-25 CN CN202180052496.5A patent/CN116194141A/zh active Pending
- 2021-08-25 WO PCT/IB2021/057794 patent/WO2022043895A2/en not_active Ceased
- 2021-08-25 MX MX2023002362A patent/MX2023002362A/es unknown
- 2021-08-25 AU AU2021330539A patent/AU2021330539A1/en active Pending
- 2021-08-25 JP JP2023513309A patent/JP2023539589A/ja active Pending
- 2021-08-25 EP EP21860686.1A patent/EP4204455A4/en active Pending
- 2021-08-25 IL IL300854A patent/IL300854A/en unknown
- 2021-08-25 CA CA3192922A patent/CA3192922A1/en active Pending
- 2021-08-25 KR KR1020237009896A patent/KR20230053686A/ko active Pending
- 2021-08-25 US US17/411,158 patent/US12528869B2/en active Active
-
2023
- 2023-02-23 JO JOJO/P/2023/0039A patent/JOP20230039A1/ar unknown
-
2025
- 2025-11-14 US US19/389,439 patent/US20260070993A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022043895A3 (en) | 2022-06-09 |
| WO2022043895A8 (en) | 2023-03-09 |
| US20220064306A1 (en) | 2022-03-03 |
| CA3192922A1 (en) | 2022-03-03 |
| MX2023002362A (es) | 2023-05-19 |
| WO2022043895A2 (en) | 2022-03-03 |
| KR20230053686A (ko) | 2023-04-21 |
| US20260070993A1 (en) | 2026-03-12 |
| JOP20230039A1 (ar) | 2023-02-23 |
| EP4204455A4 (en) | 2024-10-16 |
| JP2023539589A (ja) | 2023-09-15 |
| CN116194141A (zh) | 2023-05-30 |
| AU2021330539A1 (en) | 2023-05-04 |
| EP4204455A2 (en) | 2023-07-05 |
| US12528869B2 (en) | 2026-01-20 |
| AU2021330539A9 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250236675A1 (en) | Combination Therapies And Patient Stratification With Bispecific Ant-EGFR/C-MET Antibodies | |
| US12528869B2 (en) | Treatment of non-small cell lung cancer with EGFR mutations | |
| US12215160B2 (en) | Treatment of patients having c-met exon 14 skipping mutations | |
| US20230183360A1 (en) | Use of Amivantamab to Treat Colorectal Cancer | |
| AU2024275022A1 (en) | Methods for treatment of non-small cell lung cancer (nsclc) | |
| US20220372581A1 (en) | Methods for Identifying Cancer Patients for Combination Treatment | |
| EP4476255A1 (en) | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies | |
| WO2025153988A1 (en) | Use of amivantamab to treat colorectal cancer | |
| US20220298248A1 (en) | Treatment of Cancers Lacking EGFR- Activating Mutations | |
| US20240228634A1 (en) | Treatment of Cancers Lacking EGFR- Activating Mutations | |
| US20260048065A1 (en) | Methods for treatment of non-small cell lung cancer (nsclc) | |
| EA050561B1 (ru) | Лечение немелкоклеточного рака легкого с мутациями egfr | |
| CA3222287A1 (en) | First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer | |
| CA3228880A1 (en) | Methods of treating non-small cell lung cancer | |
| IL323279A (en) | Combination therapies with bispecific anti-EGFR/c-MET antibodies and anti-PD-1 antibodies |